Brentuximab vedotin and Rifadin IV

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

RifAMPin may cause liver problems, and using it with other medications that can also affect the liver such as brentuximab vedotin may increase that risk. You should avoid or limit the use of alcohol while being treated with these medications. Call your doctor immediately if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. RifAMPin may also reduce the blood levels of the active component of brentuximab vedotin, which may make the medication less effective in treating your condition. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: Coadministration with rifampin may decrease the plasma concentrations of monomethyl auristatin E (MMAE), the microtubule-disrupting component of brentuximab vedotin. MMAE is primarily metabolized by CYP450 3A4. In study subjects, administration of brentuximab vedotin with rifampin resulted in an approximately 46% decrease in MMAE systemic exposure (AUC). The clinical significance is unknown.

MONITOR: Coadministration of brentuximab vedotin with other agents known to induce hepatotoxicity such as rifampin may potentiate the risk of liver injury. Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with brentuximab vedotin. Cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and typically occurred after the first dose or after a rechallenge. Preexisting liver disease and elevated baseline liver enzymes may also increase the risk.

MANAGEMENT: The potential for diminished efficacy of brentuximab vedotin and increased risk of hepatic injury should be considered when brentuximab vedotin is used with rifampin. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice. Liver enzymes and bilirubin should be measured before and during treatment, especially in patients with underlying hepatic disease or marked baseline transaminase elevations. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dosage, or discontinuation of brentuximab vedotin in accordance with the product labeling.

Brentuximab vedotin

Generic Name: brentuximab

Brand name: Adcetris

Synonyms: Brentuximab Vedotin

What is Brentuximab vedotin?

Rifadin IV

Generic Name: rifampin

Brand name: Rifadin IV, Rifadin, Rimactane

Synonyms: n.a.

What is Rifadin IV?